These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12011310)

  • 21. Long-term day-case treatment of peripheral neuromuscular disease with intravenous immunoglobulin: the practice of a regional day-case service in Preston, Lancashire.
    Nixon J; McHugh C; Jones S
    Clin Med (Lond); 2013 Aug; 13(4):358-61. PubMed ID: 23908504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
    Dalakas MC
    JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
    Barsheshet A; Marai I; Appel S; Zimlichman E
    Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies.
    Sewell WA; Brennan VM; Donaghy M; Chapel HM
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):106-9. PubMed ID: 9221978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy].
    Kanda F; Sekiguchi K; Oishi K; Hamaguchi H; Mitsui S; Kobessho H; Higuchi M; Shirafuji T; Ishihara H
    Rinsho Shinkeigaku; 2006 Mar; 46(3):236-8. PubMed ID: 16642939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety monitoring of the intravenous immunoglobulin preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-interventional study.
    Bauhofer A; Dietrich RL; Schmeidl R
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):21-31. PubMed ID: 25345431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
    Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
    Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the efficacy and safety of Griflow(®) Dual, a pre-set two-flow infusion device for intravenous immunoglobulin (Flebogamma(®) 5%) administration.
    Sánchez A; Álvarez M; Bustillo MA; García MC; Muñoz M; Pacios C; Pizarroso L; Rubio MI; Rodríguez N
    J Vasc Access; 2012; 13(1):101-7. PubMed ID: 21959557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical applications of immunoglobulin in neuromuscular diseases: focus on inflammatory myopathies.
    Souza PV; Pinto WB; Oliveira AS
    Arq Neuropsiquiatr; 2014 Dec; 72(12):966-71. PubMed ID: 25465778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin and quality of life.
    Padua L; Aprile I; Caliandro P; Pazzaglia C; Tonali P
    JAMA; 2004 Sep; 292(12):1429; author reply 1429-30. PubMed ID: 15383509
    [No Abstract]   [Full Text] [Related]  

  • 31. Intravenous immunoglobulin as clinical immune-modulating therapy.
    Gilardin L; Bayry J; Kaveri SV
    CMAJ; 2015 Mar; 187(4):257-264. PubMed ID: 25667260
    [No Abstract]   [Full Text] [Related]  

  • 32. [Human immunoglobulins, adverse drug reaction, prevention].
    Grenouillet-Delacrea M; Longy-Boursier M
    Rev Med Interne; 2008 Jun; 29 Spec No 2():24-8. PubMed ID: 18927984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous immunoglobulin: facilitated infusion and advances in administration.
    Wasserman RL
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):75-7. PubMed ID: 25546770
    [No Abstract]   [Full Text] [Related]  

  • 34. [Intravenous immunoglobulin therapy in neuroimmunological disorders].
    Komoly S
    Ideggyogy Sz; 2014 Jul; 67(7-8):281-2. PubMed ID: 25509371
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
    Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
    Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
    Bussel JB; Hanna K;
    Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
    Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
    Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Summaries for patients. Improving protection against infection in people without enough immunoglobulin.
    Ann Intern Med; 2001 Aug; 135(3):S-26. PubMed ID: 11496846
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuromuscular disease: IVIg for neuromuscular disease-effective but expensive.
    Hughes RA; Lunn MP
    Nat Rev Neurol; 2012 May; 8(6):303-5. PubMed ID: 22614848
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.